BioPharmSignal logoBioPharmSignal

Biotech News

GRI Bio to Participate in the Virtual Investor Closing Bell Series

GRI Bio (GRI)GRI BioConference / presentation

Live webcast on Wednesday, May 28 th at 4:00 PM ET

LA JOLLA, CA, May 21, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=vIyWy8ojJEbqCxtSpVZ8gHCjYLnRg6tJTnk80XP_yfZ9w9DsDcWi8anMEoxvDphTfoKjVaItyb4m1ypXLRGStQ==" rel="nofollow"...

Related news

GRIGRI Bio2026-08-24 14:05 EST

GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026

GRIGRI Bio2026-06-18 13:31 EST

GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis

XGNExagen2026-07-28 13:00 EST

Exagen Inc. to Participate in Upcoming Investor Conference

AVTXAvalo Therapeutics2026-07-22 11:00 EST

Avalo Therapeutics to Participate in the BTIG Biotechnology Conference

REGNRegeneron Pharmaceuticals2026-08-19 20:05 EST

Regeneron Announces Investor Conference Presentations

KNSAKiniksa2026-05-29 20:01 EST

Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences

EQEquillium, Inc.2026-05-28 20:05 EST

Equillium to Participate in the 2026 Jefferies Global Healthcare Conference

ACRSAclaris Therapeutics2026-05-28 12:30 EST

Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

KYMRKymera2026-05-27 11:00 EST

Kymera Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference

BMYBMYBristol-Myers Squibb Company2026-05-27 10:59 EST

Bristol Myers Squibb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

View all latest news

GRI Bio

BioRestorative or GRI is a historical small-cap biotech entry tied to biologics and regenerative or related platform work. Its story is best understood as an early-stage development attempt rather than a mature commercial franchise.

Recent company news

GRIGRI Bio2026-08-24 14:05 EST

GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026

GRIGRI Bio2026-06-18 13:31 EST

GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis

GRIGRI Bio2026-05-14 13:35 EST

GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline

GRIGRI Bio2026-05-14 13:35 EST

GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline

GRIGRI Bio2026-05-14 08:35 EST

GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline

Stock data

Close
1.65 USD
Market cap
3.56M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States